Angioscaff

(standing for Angiogenesis-inducing Bioactive and Bioresponsive Scaffolds in Tissue Engineering)

will develop highly innovative

and cutting edge tissue engineering approaches for the treatment of a wide variety

of degenerative diseases which so far have limited successful and effective therapies.

Angioscaff - At is half way point

Coordinated by Professor Jeffrey Hubbell from the Ecole Polytechnique Federale de Lausanne, with over 30 groups from

leading European and Israeli academic centres, small industries and large pharma companies in full partnership.

The specific strategies being implemented are:

·  Radical innovations in state-of-the-art biomaterials

·  Design and production of advanced bioactive scaffolds enabling internal growth of tissue and the site specific delivery of bioactive

   signaling factors, that control cell differentiation

·  Injectable biomaterials and effective delivery device design that can induce angiogenesis in the body,

·  Development of bioresorbable, highly porous, and structurally sound tissue-engineered scaffolds,

·  Functionalized biomaterials that have direct influence on cell behavior,

·  Bioactive scaffolds with broad applicability for complex tissues

For the stimulating the regeneration of the Peripheral vascular system; Cardiovascular system; Bone; Skin; Central nervous system;

Peripheral Nervous system or Muscle  after damage or because of disease:

The unique combination of expertise and resources bringing together globally recognised specialists, to achieve these objectives

could only be performed via the financial support of the European Commission through the Seventh framework Programme

Nanosciences, Nanotechnologies, Materials and Production priority who are providing nearly 12 million euros of funding from

2008 to 2012.